Three months after Roche backed out of a deal to co-develop tissue-based tests, including a potential rival to Genomic Health's trailblazing Oncotype Dx, Epigenomics is looking for a new platform for diagnostics and is expanding its pipeline, the company said last week.

Specifically, Epigenomics has added a blood-based lung cancer screening test to its pipeline that it intends to develop alone for the time being, Oliver Schacht, Epigenomics CFO, told Pharmacogenomics Reporter in an interview.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

Two researchers have found that behavioral genetic defenses in criminal cases don't tend to affect outcomes, according to Popular Science.

Researchers report that while host genetics influence the oral microbiome, they don't appear to affect cavity-causing microbes, the Economist says.

Pandas' gut microbiomes change as what they eat changes with the seasons, writes Discover's Inkfish blog.

In PLOS this week: comparative genomic study of malaria-linked macaque parasite, search for apple root reference genes, and more.